Abstract

In the past decades, transcriptomic studies have revolutionized cancer treatment and diagnosis. However, tumor sequencing strategies typically result in loss of spatial information, critical to understand cell interactions and their functional relevance. To address this, we investigate spatial gene expression in HER2-positive breast tumors using Spatial Transcriptomics technology. We show that expression-based clustering enables data-driven tumor annotation and assessment of intra- and interpatient heterogeneity; from which we discover shared gene signatures for immune and tumor processes. By integration with single cell data, we spatially map tumor-associated cell types to find tertiary lymphoid-like structures, and a type I interferon response overlapping with regions of T-cell and macrophage subset colocalization. We construct a predictive model to infer presence of tertiary lymphoid-like structures, applicable across tissue types and technical platforms. Taken together, we combine different data modalities to define a high resolution map of cellular interactions in tumors and provide tools generalizing across tissues and diseases.

Highlights

  • In the past decades, transcriptomic studies have revolutionized cancer treatment and diagnosis

  • Breast cancer is divided into several subtypes, including HER2-positive tumors, which are defined by an enrichment of the HER2 expression by tumor cells[26,27]

  • HER2-positive tumors from eight individuals were subjected to Spatial Transcriptomics (ST) with three alternatively six sections obtained from each tumor (n = 36 sections) (Methods and Supplementary Figure 1)

Read more

Summary

Introduction

Transcriptomic studies have revolutionized cancer treatment and diagnosis. Building on decades of clinical and pre-clinical research, numerous scRNA-seq studies have analyzed tumor-associated cells, some of which mainly focused on cancer cells[4,5,6,7,8,9,10,11,12], immune cells[13,14,15,16,17,18,19], or fibroblasts[20,21,22] In these studies, cell types were split into finer distinctions based on their molecular profiles. Alternative strategies to treat HER2 cancer patients are needed

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call